Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B

BACKGROUND: Various treatment combinations of peginterferon (PEG‐IFN) and nucleos(t)ide analogues have been evaluated for chronic hepatitis B (CHB), but the optimal regimen remains unclear. AIMS: To study whether PEG‐IFN add‐on increases response compared to entecavir (ETV) monotherapy, and whether...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Aliment Pharmacol Ther
Hauptverfasser: Liem, Kin Seng, van Campenhout, Margo J. H., Xie, Qing, Brouwer, Willem Pieter, Chi, Heng, Qi, Xun, Chen, Liang, Tabak, Fehmi, Hansen, Bettina E., Janssen, Harry L. A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Hepb Sag and Hbv DNA Predict Response to Pegylated Interferon plus Entecavir
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590282/
https://ncbi.nlm.nih.gov/pubmed/30689258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15098
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge